Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Erlotinib for neoadjuvant treatment of EGFR NSCLC

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 26.10.18
Views: 909
Rating:

Dr Wen-Zhao Zhong - Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China

Dr Zhong speaks with ecancer at ESMO 2018 in Munich about the results of the CTONG 1103 trial of erlotinib versus gemcitabine plus cisplatin as a neoadjuvant treatment for patients with stage IIIA-N2 non-small cell lung cancer whose tumours have an EGFR mutation.

Dr Zhong outlines the challenge of the heterogeneity within these tumours, and the opportunity for neoadjuvant therapies within current treatment schedules.

The ORR, PFS data and tolerability support the use of erlotinib in this indication, and Dr Zhong discusses how a phase III study could place these findings alongside other treatment options for NSCLC, including immunotherapy.

ecancer's filming has been kindly supported by MSD through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

SIOG e-learning July 2017


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation